BPC-157 is a 15-amino-acid sequence originally identified in the protective proteins of gastric juice. The literature describes it as stable in gastric conditions and widely studied for reported effects on tissue repair pathways, angiogenesis signaling, and cellular migration.
BPC-157 is a synthetic pentadecapeptide sequence originally identified in gastric juice. Published literature — spanning more than two decades of work primarily from Sikiric and collaborators in Croatia — describes BPC-157 as a stable fragment of the larger Body Protection Compound first characterized in human gastric secretions.
The peptide has been the subject of a substantial body of preclinical research investigating reported effects on wound healing, tendon and ligament repair, and gastrointestinal integrity. It is notable in the literature for its reported stability under gastric conditions — resistant to hydrolysis that degrades most oral peptides — and for its activity across multiple administration routes in animal models.
Published studies describe BPC-157 as interacting with multiple signaling systems. Reported pathways include nitric oxide (NO) system modulation, VEGF/VEGFR2 signaling implicated in angiogenesis, focal adhesion kinase (FAK) pathways implicated in cellular migration, and growth hormone receptor expression in injured tissue. The literature generally describes these as convergent on a broader cytoprotective/trophic phenotype rather than a single receptor mechanism.
BPC-157 is not an FDA-approved drug for any indication. It is not approved for human use in the United States. The compound is widely available as a research chemical. In 2022, BPC-157 was added to the WADA prohibited list (S0, non-approved substances) for competitive athletics.
Supplied as a white lyophilized powder. Reported solubility is in bacteriostatic water or sodium chloride 0.9%. The lyophilized form is stable at 2–8°C for approximately 24 months; reconstituted solution under refrigeration is typically stable for several weeks. The sequence's proline-rich structure is believed to contribute to its reported stability profile.
The above summarizes published research literature. This is not medical advice, a protocol, or a recommendation for use. This compound is supplied for laboratory research only.
Every lot is tested by an independent 3rd-party analytical laboratory before release. The standard analytical panel includes reverse-phase HPLC (minimum 99.5% release spec, typically >99.9%), mass spectrometry for identity confirmation, Karl Fischer for water content, LAL assay for endotoxin (<0.25 EU/mL), bioburden, and sterility testing per USP <71>.
The resulting Certificate of Analysis PDF is attached to every order and is lookup-able by lot number after the fact.
They are structurally unrelated compounds often grouped together in the research literature because they are both studied in tissue-repair contexts. BPC-157 is a 15-amino-acid pentadecapeptide originally identified in gastric juice. TB-500 is a synthetic fragment of Thymosin β-4 — a much longer protein — with reported activity related to actin binding and cellular migration.
The two peptides have been the subject of combination-use discussion in the preclinical and gray-literature landscape, but from a chemistry standpoint they share essentially no structural similarity.
Shipped at ambient temperature in discreet, tamper-evident packaging. Lyophilized peptide powder is stable at room temperature for typical transit windows, which is why research-grade vendors ship this way without cold-chain logistics. Tracked via carrier; signature not required.
Upon receipt, store the unopened lyophilized vial refrigerated at 2–8°C and protected from light. Literature reports the lyophilized form is stable for up to 24 months under these conditions. If reconstituted per published solubility data, the solution is typically stable for several weeks at 2–8°C. Do not freeze.
BPC-157 is a 15-amino-acid synthetic pentadecapeptide with a molecular formula of C62H98N16O22 and a molecular weight of 1,419.55 Da. The full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with no post-translational modifications.
Supplied as a white to off-white lyophilized powder. The full primary structure is in the Compound Profile section above.
All compounds are synthesized by qualified partner laboratories operating under standard peptide synthesis practices. Synthesis records, raw material provenance, and release testing are documented in the lot file.
Each lot is independently verified by a 3rd-party analytical lab — not our in-house testing — before release. The COA PDF identifies the release lab, the method, and the analyst.
Domestic US shipping to all 50 states via USPS / UPS. Tracking provided at dispatch. International shipping is evaluated on a case-by-case basis due to jurisdictional import regulations.
All products offered on this site are intended for laboratory research purposes only. They are not for human consumption, oral ingestion, or any form of in-vivo use in humans or animals. These compounds are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease.
By placing an order you acknowledge that you are a qualified researcher over the age of 21 and that you assume all responsibility for handling, storage, and end use of the compounds in accordance with applicable law.
HPLC-verified. Mass-spec confirmed. Ambient-stable transit. The paperwork other vendors hope you never ask for.
⚠ ALL PRODUCTS ARE INTENDED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION, ORAL INGESTION, OR ANY FORM OF IN-VIVO USE IN HUMANS OR ANIMALS. THESE COMPOUNDS ARE NOT MEDICINES OR DRUGS AND HAVE NOT BEEN APPROVED BY THE FDA. BY PLACING AN ORDER YOU ACKNOWLEDGE YOU ARE A QUALIFIED RESEARCHER OVER THE AGE OF 21.